Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

More interventional procedures may be coming to an ambulatory surgical center near you
ASCs have their limitations, but they are also associated with several benefits for cardiologists and patients alike.
FDA clears new stent-based coronary thrombectomy system
The newly cleared system offers clinicians a new option for capturing and removing large coronary thrombi in patients undergoing primary PCI.
Is IVL safe for patients with diabetes?
New two-year data confirm that the IVL technology developed by Shockwave Medical can be used to treat diabetic patients who require PCI.
CPT code updates in 2026 will change how interventional cardiologists get paid
A variety of CPT code changes take effect in 2026, and many of them will make a direct impact on interventional cardiology. Arnold Seto, MD, spoke to Cardiovascular Business about these updates for a new video interview.
M-TEER still beneficial for high-risk patients with smaller mitral valve areas
Mitral valve surgery can be especially challenging when patients present with a small mitral valve area. When it comes to M-TEER, however, treatment still appears to be both safe and effective.

Edwards Evoque transcatheter tricuspid valve replacement TTVR

Evoque TTVR system linked to favorable outcomes in new real-world analysis

Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco.

First-in-human data highlight IVL’s potential to treat more challenging lesions

Shockwave Medical and FastWave Medical have shared new first-in-human data on their advanced IVL offerings. Both companies are focused on addressing difficult-to-cross lesions that often cause problems for cardiologists.

Recor Medical's Paradise Ultrasound Renal Denervation System

Medicare now covers renal denervation for patients with uncontrolled hypertension

This decision expands access to renal denervation to many more patients throughout the United States. Recor Medical and Medtronic both gained FDA approval for their RDN systems in 2023, and other vendors are actively developing their own treatment options.

Michael J. Mack, MD, discusses his team's seven-year update to the PARTNER 3 trial at TCT 2025 in San Francisco.

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.

Cardiovascular Research Foundation is merging with Fogarty Innovation

CRF merges with Fogarty Innovation to take healthcare innovation to the next level

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco.

Christian M. Spaulding, MD, PhD, at TCT 2025

A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed.

Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

Ancora Heart AccuCinch Ventricular Restoration System heart failure FDA

Transcatheter heart failure implant from Ancora Heart linked to positive 2-year data

The flexible device is attached to the inner wall of the left ventricle during a minimally invasive procedure. It was designed to reduce the size of the left ventricle over time.

Interventional Cardiology

More interventional procedures may be coming to an ambulatory surgical center near you

FDA clears new stent-based coronary thrombectomy system

Is IVL safe for patients with diabetes?

CPT code updates in 2026 will change how interventional cardiologists get paid

M-TEER still beneficial for high-risk patients with smaller mitral valve areas